metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results	deaths (OS) E	progression or deaths (PFS) E	RFS/DFS E
breast cancer (BC) breast cancer (BC)
versus GM-CSF
	GP2 vaccine plus GM-CSF
	Brown (GP2 plus GM-CSF vs GM-CSF), 2020 Breast Cancer Res Treat 2020; 181:391-401-. NCT00524277	RCT	breast cancer (BC)	GP2 plus GM-CSF	GM-CSF	Patients with HER2-positive, lymph node-positive breast cancer or high-risk lymph node-negative breast cancer.	89 / 91	high	inconclusive

Study

study type

Pathology

T1

T0

Patients

sample sizes

ROB

Results

deaths (OS) E

progression or deaths (PFS) E

RFS/DFS E

RCT

breast cancer (BC)

GP2 plus GM-CSF

GM-CSF

Patients with HER2-positive, lymph node-positive breast cancer or high-risk lymph node-negative breast cancer.

89 / 91